ICON Insights

ICON reports second quarter 2026 results. Quarter two revenue of $2,063.5 million, an increase of 1.4% on quarter one 2026. Net business wins in the quarter of $3,120 million; a net book-to-bill of 1.51. Read more https:...

With more than 70 COPD therapies in development, differentiation has never been more important. As development programmes become increasingly targeted, sponsors must integrate biomarker-informed strategies, patient-focu...

As more innovative therapies emerge from the APAC region, sponsors seeking global approval face increasingly complex regulatory decisions. Our latest article in PharmaTimes Magazine examines key considerations for navig...

Heart failure affects millions of people worldwide and can significantly impact quality of life. Research into new treatment approaches remains critical to improving outcomes and expanding options for patients living wit...

ICON today announced a multi-year collaboration with Anthropic to bring Claude’s AI capabilities across the clinical trial lifecycle. The collaboration further advances ICON’s digital innovation and AI strategy, and buil...

When Alyssa Gilliam joined ICON as a Clinical Trial Assistant in 1998, she expected it to be a temporary step. It became the start of a career shaped by new challenges, strong relationships and a willingness to keep lear...

Global clinical development is entering a more connected, data-driven era. While the FDA is piloting real-time clinical trials, other regulatory bodies are advancing AI and digital strategies in different ways, creating...

AI can improve speed and scale but trust still requires people. ICON’s Mia Malmenäs emphasizes that human expertise remains essential for interpreting incomplete evidence, evaluating AI outputs, applying regulatory and ...

Italy's pharmaceutical traceability system is undergoing one of its most significant transformations in decades. New legislation will introduce a hybrid serialisation model that aligns Italy more closely with EU Falsifi...

Patient safety starts long before the first neurologic mAb dose. Indication-specific safety planning and strict patient stratification are vital, from HBV screening in MS to AQP4 status in NMOSD. Read the article to dive...

If you've ever searched for pharmacovigilance and wondered what it actually means, you're not alone. While roles like Clinical Research Associate are widely recognised, pharmacovigilance is often less understood. Yet it...

Where is Agentic AI creating the greatest value today? Mia Malmenäs, Senior Principal at ICON, highlights that the strongest and most reliable ROI is currently in HTA dossier development and evidence synthesis. AI can a...